| Similar Articles |
|---|
 |
The Motley Fool
November 8, 2004
Charly Travers |
A Fantastic Cancer-Drug Deal Has Medarex hit the jackpot with MDX-010? Aside from the great financial terms, this deal is an important step in Medarex's transition from a research company to a company with commercial operations.   |
The Motley Fool
July 24, 2009
Brian Orelli |
Bristol-Myers: Eat or Be Eaten Bristol-Myers Squibb, the oft-rumored acquisition target of partner sanofi-aventis, is doing a little acquiring of its own, which might settle down the rumor mill. |
The Motley Fool
April 29, 2008
Brian Lawler |
Medarex Takes Another Hit Its lead cancer-fighting drug suffers a regulatory delay. |
The Motley Fool
January 31, 2011
Brian Orelli |
Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities. |
The Motley Fool
July 23, 2007
Brian Lawler |
Medarex Cheering for Its Partner The biopharma's partner advances one of its compounds into later stage clinical testing. Investors, take note. |
The Motley Fool
January 28, 2011
Brian Orelli |
Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff. |
The Motley Fool
October 26, 2010
Brian Orelli |
Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs. |
The Motley Fool
March 5, 2010
Brian Orelli |
How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot. |
The Motley Fool
December 8, 2006
Brian Lawler |
Medarex Takes the Fast Route Medarex's lead drug gets an important yet expected designation from the FDA. Making a pharmaceutical company investment-worthy requires success in the clinic and the laboratory, but it also mandates that companies handle their finances correctly. |
The Motley Fool
January 8, 2010
Brian Orelli |
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. |
The Motley Fool
November 18, 2004
Charly Travers |
A Glimpse of Bristol-Myers' Portfolio Late-stage drugs are crucial for a company beset with patent losses. |
The Motley Fool
July 15, 2008
Brian Orelli |
Will a New Use Help Schering-Plough's Near-Blockbuster Drug? Delaying relapses probably won't be enough to get its Pegintron approved as a treatment for melanoma. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
The Motley Fool
September 30, 2010
Brian Orelli |
Bristol-Myers' Delayed Steal ZymoGenetics price tag looks more reasonable. |
The Motley Fool
May 22, 2007
Mike Havrilla |
An Emergent Opportunity The vaccine developer guided for revenue growth of 10% to 15% for this year. Emergent also has a strong balance sheet, with more than $67 million in cash and investments. Investors, take note. |
The Motley Fool
June 23, 2009
Brian Orelli |
Wonder Drug! Maybe? Get the facts before jumping on this one. |
HHMI Bulletin
Nov 2010
Amy Maxmen |
Driving the Immune System to Attack Cancer A researcher's longtime efforts to drive T cells to attack tumors hits pay dirt. |
The Motley Fool
April 29, 2011
Brian Orelli |
Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves. |
The Motley Fool
May 29, 2008
Brian Lawler |
Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing. |
BusinessWeek
January 29, 2007
Arlene Weintraub |
More Merger Mania Ahead For Pharma The scramble for new drugs is keeping companies on the prowl. |
The Motley Fool
July 10, 2008
Brian Lawler |
Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks. |
Reactive Reports
Issue 58 |
Anthrax Detector Researchers have developed a detector for anthrax spores based on a monoclonal antibody that recognizes a specific sugar on the bacterium. It might be possible to use this discovery to develop a passive immunization method. |
National Defense
July 2009 |
Readers Sound Off on Recent Stories 7 Deadly Myth article draws comment. |
National Defense
June 2011
Eric Beidel |
Industry, Academia Race to Create Drugs Against Biological Warfare On the heels of anthrax comes a string of deadly agents that scientists also fear can be used as weapons and spread with ease. |
